Evidence map›Paper›PMID 38887452›Full record

SynthesisFrontiers in cardiovascular medicine2024

Global trends and research hotspots of PCSK9 and cardiovascular disease: a bibliometric and visual analysis.

Masong Tang, Sen Yang, Junying Zou, Meng Li, Yan Sun, Mengqi Wang, Wanhan Li, Junhui He, Ying Chen, Zhanyou Tang

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masong TangDepartment of Basic Medical Sciences, Medical School, University of South China, Hengyang, Hunan, China.
Sen YangDepartment of Urology, Hunan University of Medicine General Hospital, Huaihua, Hunan, China.
Junying ZouDepartment of Gynecologic, Hunan University of Medicine General Hospital, Huaihua, Hunan, China.
Meng LiDepartment of Basic Medical Sciences, Medical School, University of South China, Hengyang, Hunan, China.
Yan SunDepartment of Basic Medical Sciences, Medical School, University of South China, Hengyang, Hunan, China.
Mengqi WangDepartment of Basic Medical Sciences, Medical School, University of South China, Hengyang, Hunan, China.
Wanhan LiDepartment of Basic Medical Sciences, Medical School, University of South China, Hengyang, Hunan, China.
Junhui HeDepartment of Basic Medical Sciences, Medical School, University of South China, Hengyang, Hunan, China.
Ying ChenDepartment of Basic Medical Sciences, Medical School, University of South China, Hengyang, Hunan, China.
Zhanyou TangDepartment of Basic Medical Sciences, Medical School, University of South China, Hengyang, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular disease (CVD) is a prevalent non-communicable disease globally and holds the position of being the primary cause of mortality worldwide. Consequently, considerable focus has been directed towards the prevention and management of CVD. PCSK9, a frequently targeted element in the treatment and prevention of CVD, can reduce cardiovascular risk by effectively lowering lipid levels even in the context of statin therapy. It also exhibits substantial potential in the diagnosis and treatment of familial hypercholesterolemia from genetic aspects. This bibliometric study aims to analyze and visualize the global trends and emerging hotspots of PCSK9 and CVD researches and provide researchers with new perspectives in further studies. Methods: The data was obtained from the Web of Science Core Collection database. A total of 2,474 publications related to PCSK9 and CVD published between January 2006 and July 2023 were included. The VOSviewer was used to analyze most-cited references, co-authorship, co-citation, co-occurrence and generate a collaborative network map of authors, countries, and institutions. CiteSpace was used to analyze author and institution centroids, keyword bursts, and timeline graphs. Result: A total of 2,474 articles related to CVD and PCSK9 were included. The number of articles and citations show an increasing trend from year to year. Publications were mainly from the United States. The most active institution was Amgen Inc. Watts, Gerald F. was the most prolific author. Atherosclerosis was the most published journal. Literature co-citation and keyword co-occurrence revealed that early studies focused on the lipid-lowering effects of PCSK9 inhibitors in the context of statins therapy, long-term efficacy, adverse effects, LDLR, diagnosis and treatment of familial hypercholesterolemia. In recent years, myocardial ischemic protection, CRISPR-based editing, and new therapeutic strategies for arteriosclerotic cardiovascular disease have gotten wide attention. The protein convertase, inflammation, beta-polyacetate, and inclisiran may be the important future research directions. Conclusion: This study analyses the current status and global trends in the CVD and PCSK9 studies comprehensively, which may provide researchers and policymakers with new and comprehensive perspectives on in this field of research.

Indexed as

bibliometricscardiovascular diseasePCSK9visual analysisWOS

Identifiers

PMID38887452
PMCPMC11180773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.